Milan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.
/wp-content/uploads/2019/10/logo_enthera.svg00hearten/wp-content/uploads/2019/10/logo_enthera.svghearten2020-07-28 09:00:032020-07-28 11:35:02Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease
Enthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.
/wp-content/uploads/2019/10/logo_enthera.svg00hearten/wp-content/uploads/2019/10/logo_enthera.svghearten2018-07-24 09:11:452020-07-28 11:24:58Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing
Trianni, Inc. (“TRIANNI”) and Enthera, S.r.L. (“ENTHERA”) jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform.
Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease
/in Press Releases /by heartenMilan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.
Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing
/in Press Releases /by heartenEnthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.
Enthera and Trianni Announce Licensing Agreement
/in Press Releases /by heartenTrianni, Inc. (“TRIANNI”) and Enthera, S.r.L. (“ENTHERA”) jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform.